US

Stephen S Whitehead

This inventor holds 0 USPTO granted patents, plus 5 CIPO patents.


Average Co-Inventor Count = 1.0

ph-index = 1


Loading Chart...

Title: The Innovations of Stephen S. Whitehead

Introduction

Stephen S. Whitehead is a notable inventor based in the United States, recognized for his contributions to the field of virology. His work primarily focuses on the development of mutations that are useful for attenuating dengue viruses and chimeric dengue viruses. This innovative approach aims to enhance the efficacy of dengue virus vaccines.

Latest Patents

Stephen S. Whitehead holds a patent for the "Development Of Mutations Useful For Attenuating Dengue Viruses And Chimeric Dengue Viruses." This invention provides a flavivirus with a viral genome modified by the introduction of one or more mutations. The flavivirus may be attenuated and can exhibit phenotypes such as temperature sensitivity, host-cell restriction, or host-cell adaptation for improved replication. A comprehensive menu of mutations was developed to fine-tune the attenuation and growth characteristics of dengue virus vaccines.

Career Highlights

Stephen S. Whitehead is affiliated with the United States of America, as represented by the Secretary, Department of Health and Human Services. His work has significantly contributed to the understanding and potential treatment of dengue viruses, showcasing his expertise in the field.

Collaborations

Stephen has collaborated with notable colleagues, including Joseph E. Blaney and Brian R. Murphy. Their combined efforts have advanced research in the area of dengue virus attenuation and vaccine development.

Conclusion

Stephen S. Whitehead's innovative work in the field of virology, particularly regarding dengue viruses, highlights his significant contributions to medical science. His research continues to pave the way for advancements in vaccine development and public health.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…